Uriclear

Uriclear

Uriclear

Urinary Tract Therapy

- UriClear® Sodium bicarbonate acts as urinary alkaliser by increasing the
excretion of free bicarbonate ions in the urine, thus effectively raising the urinary
pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may
be accomplished. It also acts as antacid by chemically neutralizing or
buffering existing quantities of stomach acid but has no direct effect in its output.
This action results in increased pH value of stomach contents, thus providing
relief of hyperacidity symptoms.
Sodium Citrate and Citric Acid: Sodium citrate is metabolized to bicarbonates,
which increases urinary pH by increasing the excreting of free bicarbonate ions,
without producing systemic alkalosis when administered in recommended doses. A
rise in urinary pH increases the solubility of cystine in the urine and the
ionization or uric acid to more soluble urate ion. By maintaining an alkaline urine,
the actual dissolution of uric acid stones may be accomplished. It also reacts
chemically to neutralize or buffer existing quantities of gastric hydrochloric acid
but has no direct effects in its output. Sodium bicarbonate is excreted through
renal and also via lung by forming CO2. Sodium citrate, citric acid and absorbed
tartaric acid are excreted through urine.

Indecation

UriClear® is indicated in:
Treatment of of urinary tract infection; symptomatic relief of dysuria; to enhance
the action of certain antibiotics, especially some sulphonamides; in gout therapy as
urinary alkalinisers to prevent crystallisation of urates.

Dosage & Administration

- 1 to 2 sachets dissolved in cold water four times daily or as prescribed.

- Each sachet of UriClear® contains:
Sodium bicarbonate 1.76g
Citric acid, anhydrous 0.72g
Sodium citrate, anhydrous 0.63g
Tartaric acid 0.89g

-UriClear® is contraindicated in :
- Renal failure or hypernatremia; in conjunction with hexamine mandelate or
hexamine hippurate therapy because an acidic urine is needed.
Caution is advised in overt and occult cardiac failure. Concomitant use of urinary
alkalinisers and quinolone antibiotics should be avoided; crystalluria may be
more likely to occur in alkaline urine.tetracyclines.

- Alkalinization of the urine due to the use of UriClear®, theoretically, may result
in a deceased therapeutic effect of the following medications,chlorpropamide,
lithium, salicylates and tetracyclines.
- Alkalinization of the urine due to the use of Uriclear®, theoretically,may result
in an increased therapeutic effect of the following medications, amphetamines and
ephadrine / pseudoepherine.
-Antacid: Concurrent use of antacids with sodium citrate and sodium bicarbonate
may promote the development of calcium stones in patients with uric acid stones
and may also cause hypernatremia.
-Concurrent use at aluminium-containing antacids with salts can increase
aluminium absorption, possibly resulting in acute aluminium toxicity, especially in
patients with renal insufficiency.
-Quinolones: Citrates may reduce the solubility of ciprofloxacin, norfloxacin, or
ofloxacin in the urine. Patients should be observed for signs of crystalluria and
nephrotoxicity.
-Laxatives: Concurrent administration of citrates with laxatives may have an
additive effect.

- Studies regarding the effect of citrates on pregnancy have not been done.
- Caution should be exercised when administered to a nursing mother.

The tartrate component of UriClear® may be completely absorbed.
Because of this UriClear® may exert a mild laxative effect.
Prolonged and excessive use may cause a systemic alkalosis and / or
hypernatremia.
Contraindications:-
-Urialka® is contraindicated in patients:
- Renal failure or hypernatremia; in conjunction with hexamine mandelate or
hexamine hippurate therapy because an acidic urine is needed.
Caution is advised in overt and occult cardiac failure. Concomitant use of urinary
alkalinisers and quinolone antibiotics should be avoided; crystalluria may be
more likely to occur in alkaline urine.

- This Urialka® contains 644mg of sodium per sachet which should be taken into
account by those on a low sodium diet.

Overdose :-
- Overdosage may result in metabolic alkalosis UriClear® should be discontinued,
appropriate treatment instituted and electrolyte and acid-base determinations
should be carried out as appropriate.

- 10 sachets per pack.

- Store in a dry place below 25°C.